Skip to content
ClinCalc Pro
Menu
Nitrogen-binding agent

Glycerol phenylbutyrate

Brand names: Ravicti

Glycerol phenylbutyrate is a nitrogen-scavenging agent used as adjunctive long-term therapy in the management of urea cycle disorders that cannot be controlled by dietary protein restriction alone.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is hydrolysed to phenylbutyrate and then phenylacetate, which conjugates with glutamine to form phenylacetylglutamine; this is excreted renally, providing an alternative route for waste nitrogen elimination that bypasses the deficient urea cycle.

Prescribing in practice

  • It does not treat acute hyperammonaemic crises, which require emergency management; it is a long-term measure to maintain control alongside dietary protein restriction.
  • It is used as part of a specialist regimen including a low-protein diet and, where appropriate, amino acid supplementation under metabolic medicine supervision.
  • Reduced exposure can occur in hepatic impairment, and gastrointestinal symptoms are commonly reported.

Monitoring

Monitor plasma ammonia together with the metabolic and nutritional parameters guided by the specialist metabolic team to confirm adequate nitrogen control.

Counselling the patient

  • This medicine helps control your condition long term and must be taken alongside the prescribed diet; it is not a treatment for sudden episodes.
  • Do not stop or change the dose without advice from your metabolic team.

Evidence & guidelines

Nitrogen-scavenging therapy is an established component of chronic urea cycle disorder management used under specialist supervision.

Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.